Open AccessBisphosphonate therapy in CKD
Author(s) -
Matthew J Damasiewicz,
Thomas L. Nickolas
Publication year - 2020
Publication title -
current opinion in nephrology and hypertension/current opinion in nephrology and hypertension, with evaluated medline
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.158
H-Index - 95
eISSN - 1080-8221
pISSN - 1062-4821
DOI - 10.1097/mnh.0000000000000585
Subject(s) - medicine , kidney disease , renal osteodystrophy , bisphosphonate , chronic kidney disease mineral and bone disorder , bone remodeling , clinical trial , osteoporosis , population , bone mineral , intensive care medicine , urology , environmental health
Chronic kidney disease (CKD) is associated with the development of mineral and bone disorders (MBD), including renal osteodystrophy (ROD). ROD is a global disorder of bone strength that is associated with an increased fracture risk. The use of bisphosphonates for fracture risk reduction in CKD remains controversial. This review provides a synopsis of the state-of-the literature regarding the safety and potential antifracture benefits of bisphosphonates in CKD patients.